TSO3 Inc. J Receives a Hold from RBC Capital

By Carrie Williams

Wall Street analyst has provided a review for the Healthcare company on March 12, but retained the same rating on the stock. TSO3 Inc. J (TSX: TOS) received a Hold on March 12 from RBC Capital’s analyst Douglas Miehm, with a C$1.75 price target.

According to TipRanks.com, Miehm is ranked 0 out of 5 stars with an average return of -9.9% and a 37.0% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences Inc, Novelion Therapeutics Inc, and Aurinia Pharmaceuticals.

TSO3 Inc. J has an analyst consensus of Moderate Buy, with a price target consensus of C$2.31.

TSO3 Inc. J’s market cap is currently C$104M and has a P/E ratio of 0.

TSO3, Inc. engages in the business of medical devices. Its activities include manufacturing, sale; research and development, licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices.

The company’s shares closed on Wednesday at C$1.13, close to its 52-week low of C$1.05.